Banco Bradesco Reports Mixed 1Q26 Earnings with Net Income Decline Amidst Strategic Healthcare Consolidation and Capital Actions
Summary
Banco Bradesco reported a decline in 1Q26 net income and net interest income year-over-year, but saw growth in fee income and insurance services, alongside the finalization of its healthcare business consolidation and approval of a significant dividend payment.
Key Events
-
1Q26 Financial Performance
Net income attributable to shareholders of the parent decreased to R$5.18 billion in 1Q26 from R$5.60 billion in 1Q25. Basic earnings per common share declined to R$0.47 from R$0.50, and preferred shares to R$0.51 from R$0.56.
-
Net Interest Income Decline
Net interest income significantly decreased to R$17.33 billion in 1Q26, down from R$22.35 billion in 1Q25.
-
Revenue Growth in Other Segments
Fee and commission income increased to R$7.88 billion (from R$7.30 billion) and insurance services result grew to R$3.79 billion (from R$2.46 billion). Total deposits expanded by 20.8% and the expanded loan portfolio grew by 8.4% year-over-year.
-
Healthcare Business Consolidation Finalized
The corporate reorganization to consolidate Bradesco's healthcare business under Odontoprev S.A. (to be renamed Bradsaúde S.A.), with Bradesco holding a 91.35% interest, was approved in April 2026. This strategic move aims to simplify the corporate structure and capture operational and commercial synergies.
Analysis
Banco Bradesco's first-quarter 2026 results present a mixed financial picture, with a notable decline in net income and net interest income compared to the prior year. However, the company demonstrated strength in other revenue streams, including fee and commission income and insurance services, alongside significant growth in deposits and its loan portfolio. The quarter was also marked by the finalization of a major corporate reorganization to consolidate its healthcare business, a strategic move aimed at simplifying structure and capturing synergies. Furthermore, the company approved a substantial non-dilutive capital increase from reserves and a significant dividend payment, signaling active capital management and commitment to shareholder returns despite the profitability headwinds. Investors will likely focus on the bank's ability to improve core net interest income in future quarters while continuing to realize benefits from its strategic initiatives.
At the time of this filing, BBD was trading at $3.75 on NYSE in the Finance sector, with a market capitalization of approximately $38.3B. The 52-week trading range was $2.26 to $4.30. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.